Skip to main content
. 2017 Feb 21;292(15):6202–6212. doi: 10.1074/jbc.M116.772996

Figure 3.

Figure 3.

Prevalence of treatment-emergent (TE) NS3 amino acid substitutions as a percentage of all TE NS3 substitutions observed in GT1a virologic failures (n = 37) treated with a grazoprevir-containing regimen in phase 2 and 3 clinical trials. The type of substitution and number of virologic failures detected with that TE substitution is indicated. Note that the number of patients in whom substitutions were detected is indicated in parentheses: V36L (1); V36M (3); Y56F (1); Y56H (5); V107I (2); R155I (1); R155K (1); A156G (2); A156T (11); A156V (1); V158I (2); D168A (13); D168G (1); D168N (1); D168V (2); and D168Y (1).